Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress — Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

Intuitive Venture PartnersSeptember 15, 2025entera bio, 2025